 Risha Gidwani
Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicare | 9 | 2022 | 706 | 3.470 |
Why?
| | Deductibles and Coinsurance | 2 | 2025 | 11 | 1.870 |
Why?
| | Neoplasms | 10 | 2023 | 2449 | 1.610 |
Why?
| | Quality of Health Care | 4 | 2020 | 602 | 1.340 |
Why?
| | Hospice Care | 4 | 2019 | 192 | 1.200 |
Why?
| | Insurance, Health | 3 | 2025 | 265 | 1.160 |
Why?
| | Terminal Care | 4 | 2020 | 214 | 1.150 |
Why?
| | Lumbar Vertebrae | 4 | 2016 | 231 | 1.090 |
Why?
| | Oncologists | 2 | 2018 | 35 | 1.080 |
Why?
| | Veterans | 8 | 2020 | 1374 | 1.060 |
Why?
| | Ambulatory Care | 2 | 2020 | 504 | 1.040 |
Why?
| | United States | 25 | 2025 | 13828 | 1.030 |
Why?
| | United States Department of Veterans Affairs | 7 | 2020 | 623 | 1.000 |
Why?
| | Health Status | 2 | 2025 | 754 | 0.990 |
Why?
| | Hepatitis C, Chronic | 2 | 2019 | 153 | 0.960 |
Why?
| | Hospitals, Veterans | 5 | 2020 | 243 | 0.940 |
Why?
| | Telemedicine | 2 | 2024 | 789 | 0.930 |
Why?
| | Cost Sharing | 1 | 2024 | 14 | 0.910 |
Why?
| | Insurance, Health, Reimbursement | 2 | 2015 | 93 | 0.910 |
Why?
| | Health Care Reform | 2 | 2015 | 101 | 0.890 |
Why?
| | Financial Management | 1 | 2023 | 15 | 0.870 |
Why?
| | Venous Thrombosis | 2 | 2015 | 175 | 0.830 |
Why?
| | Patient Acceptance of Health Care | 3 | 2024 | 757 | 0.820 |
Why?
| | Pulmonary Embolism | 2 | 2015 | 211 | 0.810 |
Why?
| | Risk Adjustment | 2 | 2020 | 79 | 0.810 |
Why?
| | Medical Overuse | 3 | 2016 | 30 | 0.750 |
Why?
| | Chronic Disease | 4 | 2025 | 1715 | 0.740 |
Why?
| | Veterans Health | 2 | 2020 | 177 | 0.710 |
Why?
| | Guideline Adherence | 1 | 2025 | 526 | 0.700 |
Why?
| | Hospitalization | 4 | 2020 | 2052 | 0.700 |
Why?
| | Aged | 21 | 2025 | 22032 | 0.690 |
Why?
| | Eligibility Determination | 1 | 2020 | 63 | 0.670 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 201 | 0.660 |
Why?
| | Breast Neoplasms | 2 | 2021 | 2140 | 0.630 |
Why?
| | Fee-for-Service Plans | 1 | 2019 | 87 | 0.620 |
Why?
| | Comorbidity | 2 | 2021 | 1544 | 0.620 |
Why?
| | Patient Admission | 1 | 2020 | 181 | 0.600 |
Why?
| | Public Health | 1 | 2023 | 484 | 0.600 |
Why?
| | Medicare Part C | 1 | 2018 | 28 | 0.570 |
Why?
| | Cancer Survivors | 1 | 2022 | 257 | 0.570 |
Why?
| | Humans | 42 | 2025 | 129248 | 0.570 |
Why?
| | Cost-Benefit Analysis | 5 | 2025 | 569 | 0.560 |
Why?
| | Low Back Pain | 2 | 2016 | 105 | 0.560 |
Why?
| | Female | 29 | 2025 | 68543 | 0.550 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 279 | 0.540 |
Why?
| | Length of Stay | 2 | 2019 | 1120 | 0.540 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1004 | 0.530 |
Why?
| | Retrospective Studies | 13 | 2023 | 14455 | 0.530 |
Why?
| | Vaccines | 1 | 2022 | 398 | 0.530 |
Why?
| | Efficiency, Organizational | 1 | 2017 | 133 | 0.520 |
Why?
| | Patient Care Management | 1 | 2016 | 56 | 0.520 |
Why?
| | Palliative Care | 4 | 2017 | 706 | 0.520 |
Why?
| | Menorrhagia | 2 | 2013 | 20 | 0.520 |
Why?
| | Decision Making | 2 | 2020 | 849 | 0.510 |
Why?
| | Intrauterine Devices, Medicated | 2 | 2013 | 28 | 0.510 |
Why?
| | Middle Aged | 19 | 2025 | 31087 | 0.500 |
Why?
| | Physicians, Family | 1 | 2017 | 207 | 0.500 |
Why?
| | Documentation | 1 | 2017 | 184 | 0.490 |
Why?
| | Job Satisfaction | 1 | 2017 | 201 | 0.480 |
Why?
| | Intensive Care Units | 2 | 2019 | 736 | 0.470 |
Why?
| | Male | 24 | 2025 | 63501 | 0.460 |
Why?
| | Consumer Health Information | 1 | 2015 | 49 | 0.460 |
Why?
| | Proline | 1 | 2014 | 76 | 0.440 |
Why?
| | Endometrial Ablation Techniques | 1 | 2013 | 2 | 0.430 |
Why?
| | Emergency Service, Hospital | 3 | 2015 | 1896 | 0.430 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2014 | 130 | 0.430 |
Why?
| | Menstruation | 1 | 2013 | 44 | 0.420 |
Why?
| | Family Practice | 1 | 2017 | 455 | 0.420 |
Why?
| | Patient Satisfaction | 1 | 2017 | 632 | 0.420 |
Why?
| | Antiviral Agents | 2 | 2019 | 712 | 0.410 |
Why?
| | Attitude of Health Personnel | 3 | 2018 | 1094 | 0.410 |
Why?
| | Oligopeptides | 1 | 2014 | 258 | 0.400 |
Why?
| | Spinal Fusion | 1 | 2014 | 228 | 0.360 |
Why?
| | AIDS Serodiagnosis | 1 | 2011 | 23 | 0.350 |
Why?
| | Internet | 1 | 2015 | 615 | 0.350 |
Why?
| | Azacitidine | 1 | 2011 | 139 | 0.340 |
Why?
| | Myelodysplastic Syndromes | 1 | 2011 | 129 | 0.330 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 827 | 0.290 |
Why?
| | Hospices | 3 | 2018 | 86 | 0.290 |
Why?
| | Neoplasm Staging | 2 | 2021 | 1290 | 0.280 |
Why?
| | Disease Progression | 1 | 2015 | 2630 | 0.280 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3386 | 0.280 |
Why?
| | Administrative Claims, Healthcare | 2 | 2018 | 26 | 0.270 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1267 | 0.270 |
Why?
| | California | 3 | 2025 | 400 | 0.270 |
Why?
| | Adult | 11 | 2025 | 35495 | 0.260 |
Why?
| | Quality-Adjusted Life Years | 2 | 2025 | 106 | 0.260 |
Why?
| | Mass Screening | 2 | 2011 | 1149 | 0.260 |
Why?
| | Primary Health Care | 1 | 2016 | 1678 | 0.260 |
Why?
| | Hepacivirus | 2 | 2019 | 235 | 0.240 |
Why?
| | Taxes | 1 | 2025 | 11 | 0.240 |
Why?
| | Carbonated Beverages | 1 | 2025 | 16 | 0.240 |
Why?
| | Logistic Models | 2 | 2023 | 1984 | 0.230 |
Why?
| | Interviews as Topic | 2 | 2018 | 704 | 0.220 |
Why?
| | Pandemics | 2 | 2023 | 1482 | 0.220 |
Why?
| | Hospitals, Private | 1 | 2023 | 12 | 0.220 |
Why?
| | Aged, 80 and over | 6 | 2024 | 7055 | 0.210 |
Why?
| | Levonorgestrel | 2 | 2013 | 37 | 0.200 |
Why?
| | Young Adult | 6 | 2025 | 12388 | 0.190 |
Why?
| | Medically Uninsured | 1 | 2022 | 126 | 0.190 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2022 | 98 | 0.190 |
Why?
| | Health Status Disparities | 1 | 2024 | 251 | 0.190 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2716 | 0.180 |
Why?
| | Privatization | 1 | 2020 | 7 | 0.170 |
Why?
| | Insurance Coverage | 1 | 2022 | 218 | 0.170 |
Why?
| | Qualitative Research | 2 | 2018 | 1215 | 0.170 |
Why?
| | Probability | 1 | 2020 | 305 | 0.160 |
Why?
| | Financing, Personal | 1 | 2019 | 26 | 0.160 |
Why?
| | HIV Infections | 2 | 2011 | 2721 | 0.160 |
Why?
| | Databases, Factual | 2 | 2014 | 1266 | 0.150 |
Why?
| | Publishing | 1 | 2020 | 140 | 0.150 |
Why?
| | Hospitals | 1 | 2023 | 630 | 0.150 |
Why?
| | Medicaid | 1 | 2023 | 431 | 0.150 |
Why?
| | Needs Assessment | 1 | 2020 | 359 | 0.150 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1197 | 0.150 |
Why?
| | Adolescent | 4 | 2025 | 20303 | 0.140 |
Why?
| | Health Expenditures | 1 | 2019 | 179 | 0.140 |
Why?
| | Cost of Illness | 1 | 2019 | 277 | 0.140 |
Why?
| | Blood Pressure | 1 | 2024 | 1736 | 0.140 |
Why?
| | Bereavement | 1 | 2017 | 48 | 0.130 |
Why?
| | Alcohol Deterrents | 1 | 2016 | 17 | 0.130 |
Why?
| | Utilization Review | 1 | 2016 | 36 | 0.130 |
Why?
| | Drug Therapy | 1 | 2015 | 80 | 0.120 |
Why?
| | Hypertension | 1 | 2024 | 1242 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 301 | 0.120 |
Why?
| | Alcohol-Related Disorders | 1 | 2016 | 118 | 0.120 |
Why?
| | Publications | 1 | 2015 | 41 | 0.120 |
Why?
| | Radiotherapy | 1 | 2015 | 185 | 0.120 |
Why?
| | Genotyping Techniques | 1 | 2014 | 72 | 0.110 |
Why?
| | Cell Phone | 1 | 2015 | 70 | 0.110 |
Why?
| | Cohort Studies | 2 | 2023 | 5408 | 0.110 |
Why?
| | Medical Informatics | 1 | 2015 | 99 | 0.110 |
Why?
| | Policy Making | 1 | 2014 | 88 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2016 | 275 | 0.110 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 537 | 0.110 |
Why?
| | Confidence Intervals | 1 | 2014 | 316 | 0.110 |
Why?
| | Ribavirin | 1 | 2014 | 91 | 0.110 |
Why?
| | Thoracic Vertebrae | 1 | 2014 | 71 | 0.110 |
Why?
| | Drug Utilization | 1 | 2014 | 171 | 0.110 |
Why?
| | Danazol | 1 | 2013 | 2 | 0.110 |
Why?
| | Interferon-alpha | 1 | 2014 | 194 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2022 | 1276 | 0.100 |
Why?
| | Interferons | 1 | 2014 | 193 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 538 | 0.100 |
Why?
| | Parents | 1 | 2022 | 1308 | 0.100 |
Why?
| | Odds Ratio | 1 | 2016 | 1018 | 0.100 |
Why?
| | Interleukins | 1 | 2014 | 241 | 0.100 |
Why?
| | Progestins | 1 | 2013 | 78 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2020 | 10199 | 0.100 |
Why?
| | Family | 1 | 2017 | 644 | 0.100 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2014 | 137 | 0.100 |
Why?
| | Respiration, Artificial | 1 | 2017 | 613 | 0.100 |
Why?
| | Quality Improvement | 1 | 2020 | 1095 | 0.100 |
Why?
| | Patient Compliance | 1 | 2016 | 563 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2003 | 0.100 |
Why?
| | Obesity | 1 | 2025 | 2879 | 0.090 |
Why?
| | Reoperation | 1 | 2014 | 541 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1040 | 0.090 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5045 | 0.090 |
Why?
| | Bayes Theorem | 1 | 2013 | 373 | 0.090 |
Why?
| | Communication | 1 | 2016 | 836 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2023 | 5382 | 0.090 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 305 | 0.080 |
Why?
| | Quality of Life | 2 | 2018 | 2685 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2016 | 970 | 0.080 |
Why?
| | Community-Based Participatory Research | 1 | 2010 | 148 | 0.080 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1049 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2636 | 0.070 |
Why?
| | Health Care Costs | 1 | 2011 | 367 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1364 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2342 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2014 | 3377 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2053 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 3233 | 0.060 |
Why?
| | Health Surveys | 1 | 2025 | 493 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2010 | 899 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2014 | 2473 | 0.050 |
Why?
| | Brazil | 1 | 2022 | 154 | 0.050 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 369 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2554 | 0.040 |
Why?
| | Disulfiram | 1 | 2016 | 14 | 0.030 |
Why?
| | Consumer Behavior | 1 | 2017 | 66 | 0.030 |
Why?
| | Taurine | 1 | 2016 | 43 | 0.030 |
Why?
| | Fructose | 1 | 2016 | 106 | 0.030 |
Why?
| | Naltrexone | 1 | 2016 | 87 | 0.030 |
Why?
| | Nursing Homes | 1 | 2017 | 157 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2015 | 140 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 2015 | 242 | 0.030 |
Why?
| | Models, Economic | 1 | 2013 | 53 | 0.030 |
Why?
| | Pregnancy, Unplanned | 1 | 2013 | 45 | 0.030 |
Why?
| | Hysterectomy | 1 | 2013 | 118 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1837 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 2015 | 640 | 0.020 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 542 | 0.020 |
Why?
| | Risk Factors | 1 | 2024 | 9745 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2010 | 129 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2010 | 254 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3079 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 1016 | 0.020 |
Why?
| | Program Evaluation | 1 | 2010 | 872 | 0.020 |
Why?
| | Pregnancy | 1 | 2013 | 6391 | 0.010 |
Why?
|
|
Gidwani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|